Case-control study of gadodiamide-related nephrogenic systemic fibrosis
- 5 June 2007
- journal article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 22 (11) , 3174-3178
- https://doi.org/10.1093/ndt/gfm261
Abstract
Background. Nephrogenic systemic fibrosis may be caused by gadolinium (Gd)-containing magnetic resonance imaging contrast agents. Most reported cases were associated with one particular agent, gadodiamide. Yet, unidentified cofactors might explain why only a minority of renal failure patients exposed to gadodiamide develop nephrogenic systemic fibrosis.Keywords
This publication has 0 references indexed in Scilit: